.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,062,652

« Back to Dashboard

Claims for Patent: 8,062,652

Title:Compositions and methods for treating precocious puberty
Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
Inventor(s): Kuzma; Petr (Princeton, NJ)
Assignee: Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA)
Application Number:11/155,822
Patent Claims: 1. A method of treating central precocious puberty comprising: implanting subcutaneously into a patient in need thereof at least one controlled release reservoir implant containing a formulation comprising histrelin or its pharmaceutically acceptable salt, the reservoir implant comprising a hydrophilic copolymer obtained from a copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers, and which implant provides an average in vivo release rate of about 60 .mu.g to about 70 .mu.g of the histrelin or its salt daily in the patient.

2. The method of claim 1, wherein said formulation comprises about 50 milligrams of histrelin or its salt.

3. The method of claim 1, wherein said histrelin is histrelin acetate.

4. The method of claim 1, wherein said implant releases a therapeutically effective amount of histrelin over about 2 months.

5. The method of claim 1, wherein said implant releases a therapeutically effective amount of histrelin over about 6 months.

6. The method of claim 1, wherein said implant releases a therapeutically effective amount of histrelin over about 12 months.

7. The method of claim 1, wherein said hydrophilic copolymer comprises 2-hydroxyethyl methacrylate and hydroxypropyl methacrylate.

8. The method of claim 7, wherein said hydrophilic copolymer further comprises a crosslinking agent.

9. The method of claim 8, wherein said crosslinking agent is trimethylolpropane trimethacrylate.

10. The method of claim 1, wherein said formulation further comprises stearic acid.

11. The method of claim 1, wherein said implant releases histrelin at a rate to maintain a mean plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml over at least two months.

12. The method of claim 1, wherein said implant releases histrelin at a rate to maintain a mean plasma concentration of histrelin of about 0.4 ng/ml to about 0.6 ng/ml over at least two months.

13. A method of treating central precocious puberty comprising: implanting subcutaneously into a patient in need thereof a controlled release reservoir implant containing a formulation comprising about 50 mg of histrelin acetate, the reservoir implant comprising a hydrophilic copolymer obtained from a copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers, and which implant provides an average in vivo release rate of about 60 .mu.g to about 70 .mu.g of the histrelin acetate daily in the patient for 12 months.

14. A method of treating central precocious puberty comprising implanting subcutaneously into a patient in need thereof an implant comprising a hydrophilic copolymer and histrelin or its pharmaceutically acceptable salt, wherein said histrelin or its salt is contained within the hydrophilic copolymer, which is obtained from a copolymerization of a mixture comprising at least two hydrophilic, ethylenically unsaturated monomers, such that histrelin or its salt is released on average at a daily in vivo release rate of about 60 .mu.g to about 70 .mu.g to maintain a mean plasma concentration of histrelin of about 0.2 ng/ml to about 2 ng/ml over at least six months.

15. The method of claim 14, wherein histrelin is released at a rate to maintain a mean plasma concentration of histrelin of about 0.4 ng/ml to about 0.6 ng/ml over at least six months.

16. The method of claim 14 in which the histrelin comprises histrelin acetate.

17. The method of claim 15 further comprising removing the implant from the patient after about 12 months.

18. The method of claim 17 further comprising inserting a new implant into the patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc